JI-101
JI-101 is an orally available multi-kinase inhibitor of VEGFR2, PDGFRβ and EphB4 with potent anti-cancer activity.
Product Specifications
CAS Number
900573-88-8
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Ephrin Receptor; PDGFR; VEGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Cardiovascular Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/JI-101.html
Purity
99.78
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(NC1=CC(Br)=CC=C1OC)NC2=CC=CC3=C2C=CN3CC4=CC(N)=NC=C4
Molecular Formula
C22H20BrN5O2
Molecular Weight
466.33
Precautions
H302, H315, H319, H335
References & Citations
[1]Gurav SD, et al. Pharmacokinetics, tissue distribution and identification of putative metabolites of JI-101 - a novel triple kinase inhibitor in rats. Arzneimittelforschung. 2012 Jan;62 (1) :27-34.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
PDGFRβ; VEGFR2/KDR/Flk-1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
